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ABSTRACT
Hepatocellular carcinoma (HCC) is a significant cause of
death worldwide. HCC is a highly vascular tumor, and
proangiogenic cytokines such as vascular endothelial
growth factor (VEGF), platelet-derived growth factor
(PDGF), and fibroblast growth factor may play crucial roles
in this disease. Sorafenib, a multikinase inhibitor that
blocks VEGFandPDGF signaling,was the first systemic ther-
apy to demonstrate improved survival in patients with ad-
vanced HCC. Several other drugs targeting VEGF are in
development. Becauseof the anticipationof eventual resis-
tance to anti-VEGF therapies, drugs that also target alterna-
tive proangiogenic pathways are being investigated.
Recent clinical and preclinical data along with ongoing
studies are reviewed. TheOncologist2013;18:430–438
Implications for Practice: Advanced hepatocellular carcinomas are refractory tomost anticancer agents. Targeting of angiogen-
esisappears tobethemostsuccessful strategytodate forextendingsurvival forpatientswithadvancedHCC.Thisarticlediscusses
ongoing studies aimed at improving upon antiangiogenic therapy.
INTRODUCTION
Liver cancer is a major problem worldwide, accounting for
more than 748,000 new cases andmore than 695,000 deaths
in2008 [1]. Thehighest liver cancer rates are found inEast and
Southeast Asia. However,Western countries have seen an in-
crease in the incidenceof liver cancer in recent decades, likely
due to increases in hepatitis C virus (HCV) infection and obesi-
ty—two of themost prominent risk factors for hepatocellular
carcinoma (HCC) [2]. HCC accounts for 85%–90% of primary
liver cancers.Most patientswith HCC presentwith advanced-
stage disease and consequently are not candidates for cura-
tive treatments, such as liver transplantation or surgical
resection [3]. Even patients who undergo resection are likely
to have recurrent disease, particularly those with larger tu-
mors or tumors displaying vascular invasion [4]. Therefore,
there is a clear need for development of additional agents in
themanagement of this disease.
HCC is usually a highly vascular tumor, thus providing an
attractive target for the development of new anticancer
drugs. Tumor angiogenesis is a complex process that is regu-
lated bymany factors (Fig. 1) [5]. Vascular endothelial growth
factor (VEGF), platelet-derived growth factor (PDGF), and ba-
sic fibroblast growth factor (FGF) all appear to play important
roles in angiogenesis in many cancers, including HCC [6]. For
instance,VEGFand its receptors1,2, and3havebeen foundto
be overexpressed relative to normal liver tissue in HCC, and
overexpression of VEGF has been correlated with poor prog-
nosis [7, 8]. VEGF expressionwas also found to increase grad-
ually during multistep hepatocarcinogenesis [9]. PDGF is
required for the recruitment of smooth muscle cells, or peri-
cytes, that surroundnewbloodvessels [10]. Pericytesarecon-
sidered to be supportive cells for endothelial cells; they play
important roles in arteriogenesis, modulation of blood flow,
and regulation of vascular permeability. Basic FGF stimulates
endothelial cellmigration,capillarybranching,andtheactivity
of proteases, which are also essential for angiogenesis [11].
FGFhas also been shown in amurinemodel system to act syn-
ergistically with VEGF in the progression of HCC [12] and has
been implicated in escape from VEGF inhibition, as discussed
herein.
SORAFENIB
Sorafenib is an oral multitargeted tyrosine kinase inhibitor
(TKI) that inhibits VEGF receptors (VEGFR)-1, VEGFR-2,
VEGFR-3, PDGF receptors (PDGFR)-, PDGFR-, c-KIT, and B-
Raf, and toa lesserdegree,manyother kinases [13]. Sorafenib
has been shown to promote apoptosis in HCC cell lines and in-
hibit angiogenesis in HCC xenografts [14]. Sorafenib was orig-
inally approved by the U.S. Food and Drug Administration
(FDA) for treating patientswith advanced-stage renal cell car-
cinoma; it has since been approved in many countries for
treating patients with advanced HCC [13].
Approval of sorafenib in the setting of HCC was based on
resultsof theSorafenibHepatocellularcarcinomaAssessment
Randomized Protocol (SHARP) study—a multicenter, phase
III, double-blind, placebo-controlled trial that compared
sorafenib to placebo in 602 patients with locally advanced or
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metastatic HCC and predominantly Child-Pugh class A liver
disease [15]. Approximately one thirdof thepatients included
in this study underwent prior embolization, but no prior sys-
temic therapy was allowed. Median overall survival (OS) was
significantly longer in the sorafenib group comparedwith the
placebo group: 10.7 versus 7.9 months, respectively (hazard
ratio [HR]: 0.69, 95% confidence interval [CI]: 0.55–0.87; p
.001). Median time to progression (TTP), according to Re-
sponse Evaluation Criteria in Solid Tumors, was also signifi-
cantly longer in the sorafenib group compared with the
placebo group: 5.5 versus 2.8months, respectively (HR: 0.58,
95% CI: 0.45–0.74; p  .001). This benefit was achieved in
spite of a radiographic response rate of only 2%. The main
treatment-related side effects were diarrhea (39% of pa-
tients), hand-foot syndrome (21%), fatigue (22%), and rash
(16%).Themagnitudeofbenefitof sorafenib intheSHARPtrial
was confirmed in another phase III study conducted in the
Asia-Pacific region (NCT00492752; ClinicalTrials.gov), in
whichthehazardratiowasremarkablysimilar,butcontroland
experimentalarmshad lowersurvivalduetoapreponderance
of high-risk factors such as poor liver function and extrahe-
patic disease [16].
Becausebothof theserandomizedtrialswererestrictedto
patients with Child-Pugh A liver disease, questions have re-
mained about use of sorafenib in patients with more ad-
vanced liver disease, for whom prognosis is known to be
significantly worse [5]. The Global Investigation of Therapeu-
ticDecisions inHepatocellularCarcinomaandof itsTreatment
with Sorafenib (GIDEON) study, initiated at the time of
sorafenib’s approval to monitor the safety of the real-world
use of sorafenib, is an ongoing global, noninterventional, pro-
spective study of patients with advanced HCC treated with
sorafenib [17]. A recent interim analysis revealed that treat-
ment-related adverse effects were similar in patients with
Child-Pugh A and B liver disease; however, a greater percent-
age of patients with Child-Pugh B liver dysfunction had to dis-
continue treatment due to adverse effects (38% vs. 23%). In
the intention-to-treat population (1,614 patients), prelimi-
nary OS was 10.5 months in the Child-Pugh A group and 4.8
months in the Child-Pugh B group. This study suggests that it
may be safe to use sorafenib in patients with a higher degree
of liverdysfunction if closeattention ispaid to sideeffects, but
median survival is very short in spite of sorafenib use. Further
study iswarranted before use of sorafenib in the Child-PughB
population is considered standard.
Because many patients’ tumors are initially refractory to
sorafenib and all tumors eventually develop secondary resis-
tance, there has been interest in combining sorafenib with
conventional chemotherapy in an effort to improve out-
comes. A phase II trial was conducted comparing doxorubicin
alone versus doxorubicin plus sorafenib in patients with ad-
vanced HCC with Child-Pugh A liver dysfunction and no prior
chemoembolization [18]. At the time of trial design and ac-
crual, doxorubicin was an accepted control treatment for
randomized trials in HCC. Compared with doxorubicin mono-
therapy, the sorafenib-doxorubicin combination was associ-
ated with significantly increased median TTP as evaluated by
radiologic progression (6.4 vs. 2.8 months; p  .02), progres-
sion-free survival (PFS; 6.0 vs. 2.7 months; p  .006), and OS
(13.7 vs. 6.5 months; p  .006). This magnitude of benefit
seems greater than that seen with sorafenib alone in the
SHARP study but, due to the lack of a sorafenib monotherapy
Figure 1. Alternative angiogenic signaling. All transcriptions noted can lead to angiogenesis.
Abbreviations: EGF, epidermal growth factor; FGF, fibroblast growth factor; HIF, hypoxia inducible factor; mTOR, mammalian target of
rapamycin; PDGF,platelet-derivedgrowth factor; SP1, specificityprotein-1; Tx, transcription;VEGF, vascular endothelial growth factor.
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group, potential synergism between sorafenib and doxorubi-
cin could not be confirmed. The study investigators appropri-
ately concluded that the combination of sorafenib and
doxorubicin should not yet be adopted into routine clinical
use. However, the results of this trial served as the basis of an
ongoing phase III Alliance (formerly Cancer and Leukemia
Group B) trial comparing sorafenib plus doxorubicin with
sorafenib alone (NCT01015833; ClinicalTrials.gov).
Theefficacyof sorafenib in theadvanced settinghas led to
the thought that antiangiogenic therapy could augment the
efficacy of embolic therapy, particularly given findings that
embolization results in transient but significant increases in
serum VEGF [19]. The Sorafenib or Placebo in Combination
with Transarterial Chemoembolization (SPACE) trial was a
large randomizedphase II trial (307patients) that randomized
patients to sorafenib 400mg twice daily or placebowith drug-
eluting bead transarterial chemoembolization (DEB-TACE)
[20]. Theprimary endpointwas time to radiologic progression
and OS was a secondary endpoint. For the sorafenib arm, the
HR for TTPwas 0.797 (95%CI: 0.588–1.080; p .072) and the
HR for OSwas 0.898 (95% CI: 0.606–1.330; p .295). The au-
thors concluded that the study met its primary endpoint of
improving TTP. However, the study was unusual in that a p
value of .15was considered significant based on the trial’s de-
sign. Overall survival data were immature. These results do
not suggest a large benefit of sorafenib in this setting, but
they do support the continuation of more definitive stud-
ies, such as the ongoing Eastern Cooperative Oncology
Group 1208 trial (transarterial chemoembolization with
sorafenib versus transarterial chemoembolization alone;
NCT01004978; ClinicalTrials.gov) in patientswith liver-only
disease.
EMERGINGANTIANGIOGENIC THERAPIES FORHCC
Phase III Trial of Sunitinib Versus Sorafenib
Several other drugs that target angiogenesis have been stud-
ied or are being evaluated in phase III trials for advanced HCC
(Tables 1, 2). One agent to report in a phase III trial against
sorafenibhasbeensunitinib. Sunitinib is anoralmultitargeted
TKI with activity against VEGFR-1, VEGFR-2, PDGFR-,
PDGFR-, c-KIT, FLT3, and various other kinases [21]. The ki-
nase inhibition spectrum of sunitinib is broader than
sorafenib and broader than most other kinase inhibitors
studied to date [22].
Based on promising phase II results, a phase III study (SUN
1170)comparingsorafenibwithsunitinibwasperformed[23].
More than 1,000 patients with Child-Pugh A liver disease and
advanced HCC were randomized between sorafenib and
sunitinib.MedianOSwas10.0months for sorafenibversus8.1
months for sunitinib (HR: 1.31, 95% CI: 1.13–1.52; p .0019)
[23].As such, thestudydidnotmeetprespecifiedendpointsof
superiority or noninferiority for sunitinib. Interestingly, PFS
was 3.0 versus 3.6 months (HR: 1.13, 95% CI: 0.98–1.29; p 
.1386) in the sorafenib and sunitinib arms, respectively. Fur-
thermore, serious adverse events were more common in the
sunitinib group than in the sorafenib group. This study was
therefore stopped early due to safety concerns with sunitinib
and statistical inferiority in OS of patients taking sunitinib
compared with sorafenib. As such, further development of
sunitinib in HCC is unlikely.
Summary of Phase II/III Trials
A relatively large number of phase II studies have now been
conductedwith alternative antiangiogenic agents. Some of
these alternative therapies could hold advantages over
sorafenib due to differential selectivity of drug targets or
could be useful in patients who have failed sorafenib.
Bevacizumab is a recombinant humanized antibody
againstVEGF isoformA(whichactsprimarily throughVEGF re-
ceptors 1 and 2) that is currently FDA-approved for treating
patients with metastatic colorectal cancer and advanced
nonsquamous non-small cell lung cancer, metastatic kidney
cancer, and glioblastoma multiforme [24]. In a phase II study
enrolling 46 patientswith unresectable HCC and Child-Pugh A
orB liverdysfunctionandnoextrahepaticmetastases, bevaci-
zumabwas given intravenously (IV) every 2weeks at a dose of
5 (n 12) or 10mg/kg (n 34) until disease progression [25].
The primary objective of this studywas to determinewhether
6-month PFS was greater than 60% in the population treated
withbevacizumab(anendpointusedbecauseresponse is con-
sidered to be unlikely with angiogenesis-targeting agents).
Thestudy found that65%ofpatientswereprogression-freeat
6 months (95% CI: 51%–79%). Median PFS was 6.9 months
(95% CI: 6.5–9.1months) andmedian OSwas an encouraging
12.4months (95%CI: 9.4–19.9months). Grade 3 or 4 adverse
events included hypertension (15%),major bleeding (11%, in-
cluding 1 fatality due to variceal bleeding), and thrombosis
(6%).Asa secondaryendpoint, significant reductions in tumor
enhancement by dynamic contrast enhanced magnetic reso-
nance imaging were documented but did not correlate with
outcome. Other phase II studies of bevacizumab have shown
similar activity [26–28]. Given the activity seen with bevaci-
zumab, it is somewhat surprising that phase III trials have not
yetoccurred forHCC.Thismay in largepartbedue toconcerns
over variceal hemorrhage. In light of this risk, the use of
screening upper endoscopy along with primary preventive
strategies may help minimize the risk of such fatal hemor-
rhages [29].
A subsequent single-armphase II trial enrolled 40patients
with advanced HCC with Child-Pugh A and Child-Pugh B liver
dysfunction to receive bevacizumab (10mg/kg every 14 days)
and daily erlotinib (150 mg), an oral epidermal growth factor
receptor (EGFR) inhibitor [30]. The result for the primary end-
point of the study (PFS at 16 weeks) was 62.5%, a figure con-
sidered positive per the trial design. Median PFS was a highly
encouraging 9.0 months (95% CI: 26–45 weeks) and median
OS was 15.7 months (95% CI: 48–78 weeks). The major ad-
verseeffectswere fatigue (20%)andhypertension (15%). Two
patients did develop life-threatening gastrointestinal bleed-
ing and one eventually died. A large randomized phase II trial
Given the activity seen with bevacizumab, it is some-
what surprising that phase III trials have not yet oc-
curred for HCC. This may in large part be due to
concerns over variceal hemorrhage. In light of this
risk, theuseof screeningupperendoscopyalongwith
primary preventive strategiesmay helpminimize the
risk of such fatal hemorrhages.
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of this combination versus sorafenib is currently ongoing to
determinewhether the regimen should proceed to a phase III
trial (NCT00881751; ClinicalTrials.gov).
VEGFR-2 signaling mediates most of the known cellular
processesenactedbyVEGF, including thepromotionof angio-
genesis in tumors [31].SignalingthroughVEGFR-1, incontrast,
appears to be only weakly involved in mediating the angio-
genic effects of VEGF [32]. No drugs that specifically inhibit
VEGFR-2 have been evaluated in patients with HCC until re-
cently. Ramucirumab is a recombinant fully humanmonoclo-
nal antibody that binds the extracellular domain of VEGFR-2.
In contrast toother anti-VEGFdrugs, suchasbevacizumab, ra-
mucirumab binds VEGFR-2 with high affinity and specificity,
preventing all VEGF ligands from binding to VEGFR-2 [33]. A
phase II studyof ramucirumabwasconducted in42previously
untreatedpatientswithChild-PughAorChild-PughB liverdys-
function [34]. Seventy-six percent of thesepatients hadextra-
hepatic disease and 49% had HCV infection. Ramucirumab
was given IV every 2weeks until disease progression.Median
PFSwas 4.2months for Child-Pugh A patients and 2.8months
Table 1. Randomized phase III antiangiogenic therapy trials







III Sorafenib Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others)
First line NCT00492752 Placebo 271 Mar. 2007
III Linifanib Multikinase inhibitor of VEGFR,
PDGFR-, CSF-1R, and others
First line NCT01009593 Sorafenib 1,100 May 2012
III Brivanib Selective inhibitor of VEGFR and FGFR
tyrosine kinases
First line BRISK FL NCT00858871 Sorafenib 1,050 Dec. 2012
III Sorafenib erlotinib Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); inhibitor of tyrosine
kinases on EGFR
First line SEARCH NCT00901901 Sorafenib
placebo
731 Dec. 2012
II/III Thalidomide capecitabine Small moleculewith antiangiogenic
properties; 5-fluorouracil that inhibits
DNA synthesis
















Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); platinum compound
that triggers apoptosis by binding to
and causing DNA crosslinking;
thymidylate synthase inhibitor
Unspecified SILIUS NCT01214343 Ministry of Health,
Labor andWelfare,
Japan
Sorafenib 190 Sept. 2013
III Sorafenib pravastatin Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); immunemodulator
withmultiple antineoplastic effects
Unspecified NCT01075555 FFCD-PRODIGE-11 Sorafenib 474 Sept. 2013
III SIR-spheres First line NCT01135056 Singapore General
Hospital
Sorafenib 360 Jul. 2015
III SIR-spheres First line SARAH NCT01482442 Assistance
Publique Hopitaux
de Paris P101103
Sorafenib 400 Mar. 2015
III Sorafenib doxorubicin Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); anthracycline
antibiotic that intercalates DNA
First line NCT01015833 CALGB-80802 Sorafenib 480 Unknown
(recruiting)
III Ramucirumab Fully humanmonoclonal antibody to
(receptor antagonist) against VEGFR-2
Second line REACH NCT01140347 Placebo 544 Apr. 2013
III Brivanib Selective inhibitor of VEGFR and FGFR
tyrosine kinases
Second line BRISK-PS NCT00825955 Placebo 414 May 2012
III Brivanib Selective inhibitor of VEGFR and FGFR
tyrosine
Second line BRISK-APS NCT01108705 Placebo 252 Sept. 2014
III Sorafenib TACE Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others)





Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); anthracycline
antibiotic that intercalates DNA






III Sorafenib Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others)
Adjuvant STORM NCT00692770 Placebo 1,115 Oct. 2014






TACE 200 Apr. 2013
II/III Thalidomide RFA Small moleculewith antiangiogenic
properties
Adjuvant LDT-RFA NCT00728078 Sun Yat-sen
University
RFA 200 Unknown
III PI-88 after surgical
resection
Highly sulfonated oligosaccharide that
inhibits heparanase activity and
competeswith heparan sulfate for
FGF and VEGF binding





III Brivanib TACE Selective inhibitor of VEGFR and FGFR
tyrosine kinases
Adjuvant BRISK TA NCT00908752 TACE
placebo
870 Mar. 2015
III Orantinib TACE Tyrosine kinase inhibitor of VEGFR-2,
PDGFR, FGFR and c-KIT
Adjuvant ORIENTAL NCT01465464 TACE
placebo
880 May 2017
III Sunitinib TACE Multireceptor kinase inhibitor (VEGFR,
PDGFR, c-KIT, RET, csf-1R, and FLT3)
Adjuvant SATURNE NCT01164202 FFCD-PRODIGE-16 TACE 190 Jul. 2013
Abbreviations: COOP, Group conducting study; if blank, the study is conducted by the drugmanufacturer; CPB, Child-Pugh B; CSF-1R, colony-
stimulating factor 1 receptor; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; NCT, National Clinical Trial; PDGFR,
platelet-derived growth factor receptor; RET, rearranged during transfection (receptor kinase); RFA, radio frequency ablation; TACE, transcatheter
arterial chemoembolization; VEGFR, vascular endothelial growth factor receptor.
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for Child-Pugh B patients. Themost common serious adverse
events were hypertension (12%), fatigue (10%), and bleeding
(7%). Anongoing phase III trial is evaluating the use of ramuci-
rumab in patients with HCC in the second-line treatment set-
ting after sorafenib (NCT0114034; ClinicalTrials.gov).
Linifanib is an orally available TKI with potent activity
againstVEGFR-1, -2,and-3andPDGFR- inkinaseassaysanda
muchmore limited kinase inhibition spectrum than sorafenib
or sunitinib [35]. In amulticenter phase II trial of linifanibwith
44 patients with advanced HCC with Child-Pugh A or B liver
dysfunction,medianOSwas10.4months (95%CI:8.4–14.9) in
the Child-Pugh A group (n 38) and 2.5months (95% CI: 1.1–
4.5) in the Child-Pugh B group (n 6) [36]. Themost common
serious side effects were hypertension (18%) and fatigue
(14%). These results suggested that linifanib is clinically active
in patientswith advancedHCCandChild-PughA liver dysfunc-
tion. A phase III study comparing linifanib to sorafenib in pa-
tients with advanced HCC and Child-Pugh A status has
completed enrollment and results are expected within the
next year (NCT01009593; ClinicalTrials.gov).
Cediranib is another potent oral TKI that (relatively)
specifically targets VEGFR-1 and -2 [37]. In a phase II study
of daily oral cediranib enrolling 28 patients with unresect-
able HCC, median OS was 5.8 months (95% CI: 3.4 –7.3
months) and the median TTP was 2.8 months (95% CI: 2.3–
4.4 months) [37]. Twenty-six patients (93%) experienced a
grade 3 or greater treatment-related adverse event; these
included fatigue, anorexia, hypertension, and elevated ala-
nine aminotransferase. Because of these toxicities, cedi-
ranib at the doses and schedule given in this trial does not
Table 2. Randomized phase II antiangiogenic therapy trials







II Vandetanib Multireceptor tyrosine kinase inhibitor
of VEGFR, EGFR, and RET
First line NCT00508001 Placebo 78 Unknown
II Sorafenib gemcitabine
oxaliplatin
Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); nucleoside analog
used as chemotherapy; DNA synthesis
inhibitor
First line NCT00941967 CCLC-GONEXT-PRODIGE-10 Sorafenib 78 Unknown
I/II Sorafenib bevacizumab Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); humanized
monoclonal antibody against VEGF-A
First line NCT00867321 NCGGT-N0745 Sorafenib 97 Unknown
(recruiting)
II Sorafenib E7050 Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); inhibitor of tyrosine
kinases on VEGFR-2 and c-Met
First line NCT01271504 Sorafenib 95 Dec. 2014
II Bevacizumab erlotinib Humanizedmonoclonal antibody
against VEGF-A; inhibitor of tyrosine
kinases on EGFR
First line NCT00881751 Medical University of South
CarolinaMUSC-101282
Sorafenib 120 Sept. 2012
II Sorafenib everolimus Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); inhibitor ofmTOR




II Dovitinib Multikinase inhibitor that targets
FGFR3, VEGFRs, FGFR1, and PDGFR
First line NCT01232296 Sorafenib 150 Jul. 2013
II Sorafenib tigatuzumab Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); humanized
monoclonal antibody against TRAIL-R2
First line NCT01033240 Sorafenib 160 Mar. 2012
II Sorafenibmapatumumab Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); humanmonoclonal
antibody against the TRAIL receptor
First line NCT01258608 Sorafenib
placebo
100 Dec. 2013
II Sorafenib doxorubicin Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others); anthracycline
antibiotic that intercalates DNA
First line SoraDox NCT01272557 Martin Luther Universitat
Halle-Wittenberg
Sorafenib 170 Sept. 2012
II TACE Unspecified STAP NCT01480817 Seoul National University
Hospital
Sorafenib 40 Sept. 2014
II Intedanib Small-molecule inhibitor that binds the
ATP-binding domain of VEGFR 1–3,
FGFR 1–3, and PDGFR- and -
First line NCT01004003 Sorafenib 115 Feb. 2013
II Intedanib Small molecule inhibitor that binds the
ATP-binding domain of VEGFR 1–3,
FGFR 1–3, and PDGFR- and -
First line NCT00987935 Sorafenib 142 Jul. 2012
II Axitinib Tyrosine kinase inhibitor of VEGFR-1,
VEGFR-2, VEGFR-3, PDGFR, and cKIT
Second line NCT01210495 Placebo 222 Jan. 2013
II Sorafenib TACE Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others)
Adjuvant TACTICS NCT01217034 Japan Liver Oncology Group
JLOG 1001
Placebo TACE 228 Sept. 2016
II Sorafenib RFA or TACE Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others)
Adjuvant SORAMIC NCT01126645 University ofMadgeburg
RAD85
Sorafenib 665 Feb. 2014
II Sorafenib TACE Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others)
Adjuvant SPACE NCT00855218 Placebo TACE 307 Mar. 2012
II Bevacizumab TACE Humanizedmonoclonal antibody
against VEGF-A
Adjuvant NCT00049322 UCLA 0206060; NCI G02–
2124
Placebo TACE 54 Jun. 2012
II Sorafenib laser ablation Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others)
Adjuvant LANEX NCT01507064 Cardarelli Hospital Laser ablation 40 Jan. 2015
II Sorafenib RFA Multikinase inhibitor (VEGFR, PDGFR,
Raf, and others)
Adjuvant NCT00813293 Beth Israel Deaconess
Medical Center
Placebo RFA 20 Unknown
(recruiting)
Abbreviations: COOP, group conducting study; if blank, the study is conducted by the drugmanufacturer; CSF-1R, colony-stimulating factor-1
receptor; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor;mTOR,mammalian target of rapamycin; NCI, National
Cancer Institute; PDGFR, platelet-derived growth factor receptor; RET, rearranged during transfection (receptor kinase); RFA, radio frequency
ablation; TACE, transcatheter arterial chemoembolization; TRAIL, tumor necrosis factor-related apoptosis inducing ligand; UCLA, University of
California Los Angeles; VEGFR, vascular endothelial growth factor receptor.
434 Antiangiogenic Therapies for Advanced HCC
©AlphaMed Press 2013
appear to be as effective or safe as other agents in the class
for patients with HCC.
Brivanib is anoral, selective, dual inhibitor of FGF receptor
(FGFR) and VEGFRs that has demonstrated potent antitumor
and antiangiogenic effects in preclinical models of various tu-
mor types, includingHCC [38, 39]. Brivanibhasalsobeenasso-
ciatedwithdelayed tumorgrowthand increased survival in an
HCC xenograftmodel of acquired resistance to sorafenib [40].
Aphase II studywas completed inpatientswithadvancedHCC
with Child-Pugh A and B liver status who did not receive prior
systemic therapy (first-line therapy cohort; n  55) [41] or
who receivedprior treatmentwith at least one regimenof an-
tiangiogenic therapy, primarily sorafenib (second-line ther-
apy cohort; n 46) [42]; 64% of these patients were Asian. In
the first-line therapy cohort, median OS was 10months (95%
CI: 6.8–15.2) and median PFS was 2.7 months (95% CI: 1.4–
3.0), based onmodifiedWorld Health Organization tumor re-
sponse criteria [41]. Interestingly, results for the second-line
therapy cohortwerenearly as goodas those for theuntreated
patients,withmedianOSof 9.79months (95%CI: 5.52–13.17)
[42].Thissuggests thatbrivanibmay in facthelpreverseoneor
more mechanisms of resistance to sorafenib, as will be dis-
cussed further below. The most common treatment-related
sideeffectswereelevated liverenzymes(87.3%ofpatientsex-
perienced elevated aspartate aminotransferase and 85.5% of
patients experienced elevated alanine aminotransferase),
proteinuria (65.5%), fatigue (45.5%), hypertension (45.5%),
nausea (38.2%), and diarrhea (41.8%) [41].
Brivanib has been or is being investigated in several phase
III trials, including first-line treatment with brivanib versus
sorafenib (BRISK-FL; NCT00858871; ClinicalTrials.gov), sec-
ond-line treatment with brivanib after progression on
sorafenib (BRISK-PS; NCT00825955; ClinicalTrials.gov), sec-
ond-line treatment with brivanib after progression on
sorafenib in patients from the Asia-Pacific region (BRISK-
APS; NCT01108705; ClinicalTrials.gov), and transarterial che-
moembolization with or without brivanib (BRISK-TA;
NCT00908752; ClinicalTrials.gov). Results from the second-
line study (after sorafenib failure) have been presented in ab-
stract form [43]. BRISK-PS randomized 395 patients in a 2:1
fashion between brivanib 800mg/day orally and placebo. Pa-
tients entering the study were required to have been treated
with sorafenib forat least14daysand thenprogressedwithor
became intolerant to sorafenib. The primary endpoint was
overall survival and the studywas statistically powered to de-
tect an HR of 0.67. The study was conducted worldwide, and
patient demographics reflected a slight preponderance of
Asian HCC characteristics. The results demonstrated an HR of
0.89withadifference inmedianoverall survival of 1.2months
favoring the brivanib arm that did not reach statistical signifi-
cance. Notably, there was increased incidence of portal vein
thrombosis with brivanib (31% in the brivanib arm vs. 18% in
the placebo arm). In spite of the study notmeeting its primary
endpoint, a differenceof 1.5months andanHRof 0.56 for TTP
appears to confirm that brivanib has some activity in this pa-
tient population. These results do not rule out the possibility
that brivanibwill meet its planned endpoints in other trials.
Phase I/II Trials
In the past, pharmaceutical companies did not sponsor trials,
especially with investigational agents, in patients with liver
disease and HCC. Currently, a large number of antiangiogenic
agentswith thepotential to affect tumor growth arebeing ex-
plored in clinical trials, withmany in earlier stages of develop-
ment. Someof themostpromisingagents include inhibitorsof
the mammalian target of rapamycin (mTOR) and multiple
growth factor signaling pathways.
The mTOR signaling pathway is broadly involved in the
translation of proteins, including proangiogenic factors (in-
cluding VEGF). Inhibition of mTOR has been explored as a po-
tential therapeutic strategy in renal cell carcinoma, a cancer
that is clearlydrivenbyVEGFproduction [44,45]. Importantly,
mTOR inhibition has been effective in tumors that are refrac-
tory to VEGF pathway inhibitors.
Aphase I/II studyhasbeencompletedusing theoralmTOR
inhibitor everolimus (at a dose of 10mg/kg/day in phase II) in
28 patients with advanced HCC and Child-Pugh A and B liver
dysfunction [46]. Inall, 71%of thepatients in this studyhadre-
ceived prior therapy, including sorafenib. Median OS was 8.4
months (95% CI: 3.9–21.1) and median PFS was 3.8 months
(95% CI: 2.1–4.6). Fatigue, hyperglycemia, and anemia were
the most common side effects associated with everolimus.
There is an ongoing global, randomized, double-blinded, pla-
cebo-controlled phase III trial investigating the use of everoli-
mus in patients after the failure of sorafenib therapy
(NCT01035229; Clinicaltrials.gov).
TSU-68 is an oral TKI that targets VEGFR-2, PDGFR, and
FGFR [47]. A phase I/II studywas performedwith TSU-68 in 35
patientswith advancedHCCwith Child-PughAandB liver dys-
function [47]. None of these patients had been treated with
sorafeniband83%wereHCVpositive.ThemedianOSwas13.1
months (95% CI: 6.9–26.6), although TTP was discordant at a
median of 2.1months (95% CI: 1.2–2.9). Themain treatment-
relatedadverseevents associatedwithTSU-68werediarrhea,
anorexia, andabdominalpain.Basedon thepromisingactivity
shown in thisphase I/II trial, aphase III trial is currently recruit-
ing participants.
RESISTANCE TOANTIANGIOGENIC AGENTS
The approval of sorafenib marked a major milestone in the
treatment of advanced HCC and has opened the door for
the development of additional antiangiogenic agents.
However, antiangiogenic agents have not been as success-
ful as initially imagined, not only in HCC but also in other
solid tumors [48, 49]. Tumors typically respond initially to
anti-VEGF therapies with stability (rarely shrinkage), then
quickly become resistant.
Several mechanisms have been proposed to explain how
cancers resistVEGF inhibition.Thereappears tobeadaptiveor
evasive resistance toVEGF inhibitionalongwith intrinsic resis-
tance [48]. The upregulation of alternative proangiogenic sig-
naling pathwayswithin tumors is thought to circumvent VEGF
inhibition; a well-described alternative signaling pathway in-
volves FGF and the FGFRs [50]. In a preclinical pancreatic neu-
roendocrine tumormodel, FGF levels were noted to bemuch
higher in tumors treatedwithVEGF inhibitorswhencompared
with untreated tumors [51]. Furthermore, VEGF inhibition
with concurrent FGF blockade showed decreased tumor
growth compared to VEGF inhibition alone. A clinical study of
5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab
in patientswithmetastatic colon cancer showed that FGF lev-
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elswereelevated inpatientplasmabothprior toandafterdis-
easeprogression [52]. Several other cytokines andangiogenic
factors were also significantly elevated in patient plasma
(compared to baseline) before measurable radiographic pro-
gression, including hepatocyte growth factor, placental
growth factor, stromal-derived factor-1, and macrophage
chemoattractantprotein-3 [52]. Recently, upregulationof the
FGF-8 subfamily has been shown to promote tumor cell sur-
vival in HCC [53].
Because of structural similarities in the kinase domains of
several growth factor receptors, some TKIs have multiple-re-
ceptor specificity. It is therefore not surprising that ongoing
clinical trials include agents such as brivanib, dovitinib, and
BIBF 1120 that target both FGFR and VEGFR. These studies
mayprovide interesting information aboutwhether dual inhi-
bition of FGFR and VEGFR is more effective in the front-line
setting or around the time of progression.
Acquired resistance toVEGF inhibitionmayalsobe related
to changes in vascular stromal cells [54]. In amouse xenograft
model of non-small cell lung adenocarcinoma, increased ex-
pression of components of the EGFR and FGFR signaling path-
ways were evident in the gene expression profile of the
stromal cell compartment [54]. In bevacizumab-resistant tu-
mors, pericytes expressed higher levels of EGFR than control
(non-bevacizumab resistant) tumors. Furthermore, bevaci-
zumab-resistant tumors exhibited an increase in pericyte cov-
erage of vessels—a necessary step in angiogenesis. Targeting
both the EGFR and VEGF pathways with bevacizumab and er-
lotinib in mouse xenografts significantly delayed the onset of
therapeutic resistance compared with inhibition of either
pathway alone [54]. This suggests that tumors may switch
from VEGFR- to EGFR-driven angiogenesis as resistance oc-
curs, and itmay explain the efficacy of the bevacizumab/erlo-
tinib combinationmentioned earlier.
FUTUREDIRECTIONS FORANTIANGIOGENIC THERAPY
Proteins other than growth factors play key roles in tumor an-
giogenesis andmay eventually serve as therapeutic targets in
the quest to prevent resistance to antiangiogenic treatment.
For example, hypoxia inducible factor (HIF)-1, a proangio-
genic transcription factorupstreamofVEGFandFGF,maypar-
ticipate in resistance to VEGF inhibition [55]. Increased tumor
hypoxia due to VEGF inhibition has been shown to lead to in-
creased expression of HIF-1. In a non-HCC mouse xenograft
model, theadditionof topotecan,apotentHIF-1 inhibitor, to
bevacizumab treatment led to significant reduction in tumor
growth compared to bevacizumab or topotecan treatment
alone [55]. Similarly, specificity protein (SP)-1 is another
transcription factor that is involved in the expression of
VEGF and other proangiogenicmediators [56]. Inhibition of
SP-1 with mithramycin A appears to have antiangiogenic
and antitumor activity in mouse pancreatic cancer xeno-
grafts [56]. These preclinical studies suggest that targeting
transcription factors such as HIF-1 and SP-1 (with drugs)
would be a worthwhile strategy to investigate in tumors
with robust angiogenesis.
Blood vessel integrity and normalization are emerging as
critical parts of understanding angiogenesis in cancer [57].
The angiopoietin (ANGPT)-TIE (tyrosine kinase with immuno-
globulin-like andEGF-likedomains) system is thought tobe in-
timately involved in vascular maintenance. ANGPTs are
ligands that bind to TIE-2 receptors on vascular endothelial
cells [58], influencing the maintenance of existing blood ves-
sels andmaturation of new vessels. To take advantage of this
interaction, several drugs targeting the ANGPTs and TIE2 are
currently in development for solid tumors andmay represent
an additional opportunity to target tumor vasculature [58].
VEGF and VEGFR-targeting therapy has represented the
first real success inHCC inmanyyears, reinvigorating research
in this deadly and difficult malignancy. The success of target-
ingVEGF receptorsnowneeds tobe followedbybetterunder-
standingofmechanismsof intrinsicandacquiredresistance to
these agents. As our understanding evolves, next-generation
anti-VEGFR agents and agents targeting alternative proangio-
genic pathways hold significant promise for the treatment of
HCC.
At present, the lack of good radiographic and biologic bio-
markers remains anadditional challenge for thedevelopment
of effective therapies for HCC. However, using newer imaging
modalities to detect early biologic changes is an active area of
research. For example, a small retrospective study demon-
strated that baseline positron emission tomography-com-
puted tomography (PET-CT) scansmay predict OS and PFS for
patientswhoundergo treatmentwith sorafenib [59]. Imaging
techniques such as computed tomography or magnetic reso-
nanceperfusion imagingandPET-CTholdpromise inassessing
responses in HCC and will aid the development of biologic
therapies in the future [60].
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VEGF and VEGFR-targeting therapy has represented
the first real success in HCC in many years, reinvigo-
rating research in this deadly and difficult malig-
nancy. The success of targeting VEGF receptors now
needs to be followed by better understanding of
mechanisms of intrinsic and acquired resistance to
these agents. As our understanding evolves, next-
generation anti-VEGFR agents and agents targeting
alternative proangiogenic pathways hold significant
promise for the treatment of HCC.
436 Antiangiogenic Therapies for Advanced HCC
©AlphaMed Press 2013
REFERENCES
1. Jemal A, Bray F, CenterMMet al. Global cancer
statistics. CA Cancer J Clin 2011;61:69–90.
2. El-Serag HB, Rudolph KL. Hepatocellular carci-
noma:Epidemiologyandmolecular carcinogenesis.
Gastroenterology 2007;132:2557–2576.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular
carcinoma. Lancet 2003;362:1907–1917.
4. Nathan H, Schulick RD, Choti MA et al. Predic-
tors of survival after resection of early hepatocellu-
lar carcinoma. Ann Surg 2009;249:799–805.
5. Thomas MB, Jaffe D, Choti MM et al. Hepato-
cellular carcinoma: Consensus recommendations
of the National Cancer Institute Clinical Trials
Planning Meeting. J Clin Oncol 2010;28:3994 –
4005.
6. FernándezM, Semela D, Bruix J et al. Angiogen-
esis in liver disease. J Hepatol 2009;50:604–620.
7. Dhar DK, Naora H, Yamanoi A et al. Requisite
role of VEGF receptors in angiogenesis of hepato-
cellular carcinoma: A comparison with angiopoi-
etin/Tie pathway. Anticancer Res 2002;22:379–
386.
8. Tseng PL, Tai MH, Huang CC et al. Overexpres-
sion of VEGF is associated with positive p53 immu-
nostaining in hepatocellular carcinoma (HCC) and
adverse outcome of HCC patients. J Surg Oncol
2008;98:349–357.
9. Park YN, Kim YB, Yang KM et al. Increased ex-
pression of vascular endothelial growth factor and
angiogenesis in theearly stageofmultistephepato-
carcinogenesis. Arch Pathol Lab Med 2000;124:
1061–1065.
10. Conway EM, Collen D, Carmeliet P. Molecular
mechanismsofbloodvesselgrowth.CardiovascRes
2001;49:507–521.
11. Javerzat S, Auguste P, Bikfalvi A. The role of fi-
broblast growth factors in vascular development.
TrendsMolMed 2002;8:483–489.
12. Yoshiji H, Kuriyama S, Yoshii J et al. Synergistic
effect of basic fibroblast growth factor and vascular
endothelial growth factor in murine hepatocellular
carcinoma. Hepatology 2002;35:834–842.
13. Nexavar [package insert]. Wayne, NJ: Bayer
Healthcare Pharmaceuticals, 2011.
14. Huynh H, Ngo VC, Koong HN et al. Sorafenib
and rapamycin induce growth suppression in
mouse models of hepatocellular carcinoma. J Cell
MolMed 2009;13:2673–2683.
15.Llovet JM,Ricci S,MazzaferroVetal. Sorafenib
inadvancedhepatocellular carcinoma.NEngl JMed
2008;359:378–390.
16. Cheng AL, Kang YK, Chen Z et al. Efficacy and
safety of sorafenib in patients in the Asia-Pacific re-
gion with advanced hepatocellular carcinoma: A
phase III randomised, double-blind, placebo-con-
trolled trial. Lancet Oncol 2009;10:25–34.
17.Marrero JA, LencioniR, KudoMetal.Global in-
vestigation of therapeutic decisions in hepatocellu-
lar carcinoma and of its treatment with sorafenib
(GIDEON) second interim analysis in more than
1,500patients:Clinical findings inpatientswith liver
dysfunction. J Clin Oncol 2011;29(suppl 15):4001.
18.Abou-AlfaGK, JohnsonP,Knox JJ et al.Doxoru-
bicin plus sorafenib vs doxorubicin alone inpatients
with advanced hepatocellular carcinoma: a ran-
domized trial. JAMA 2010;304:2154–2160.
19. Shim JH, Park JW, Kim JH et al. Association be-
tween increment of serum VEGF level and progno-
sis after transcatheter arterial chemoembolization
in hepatocellular carcinoma patients. Cancer Sci
2008;99:2037–2044.
20. Lencioni R, Llovet JM, HanGet al. Sorafenib or
placebo in combination with transarterial chemo-
embolization (TACE) with doxorubicin-eluting
beads (DEBDOX) for intermediate-stage hepatocel-
lular carcinoma (HCC): Phase II, randomized, dou-
ble-blind SPACE trial. ASCO Meeting Abstracts
2012;30:LBA154.
21.Mendel DB, Laird AD, Xin X et al. In vivo antitu-
moractivityofSU11248,anovel tyrosinekinase inhib-
itor targeting vascular endothelial growth factor and
platelet-derived growth factor receptors: Determina-
tion of a pharmacokinetic/pharmacodynamic rela-
tionship. ClinCancerRes2003;9:327–337.
22.Weis SM, Cheresh DA. Tumor angiogenesis:
Molecular pathways and therapeutic targets. Nat
Med 2011;17:1359–1370.
23. Cheng A, Kang Y, Lin D et al. Phase III trial of
sunitinib (Su) versus sorafenib (So) in advanced
hepatocellular carcinoma (HCC). J Clin Oncol 2011;
29(suppl 15):Abstract 4000.
24. Avastin [package insert]. South San Francisco,
CA: Genetech Inc 2009.
25. Siegel AB, CohenEI, OceanAet al. Phase II trial
evaluating theclinical andbiologiceffectsofbevaci-
zumab in unresectable hepatocellular carcinoma.
J Clin Oncol 2008;26:2992–2998.
26. SunW, Sohal D, Haller DG et al. Phase 2 trial of
bevacizumab,capecitabine,andoxaliplatin in treat-
ment of advanced hepatocellular carcinoma. Can-
cer 2011;117:3187–3192.
27.HsuCH, Yang TS,HsuCet al. Efficacy and toler-
ability of bevacizumab plus capecitabine as first-
line therapy in patients with advanced
hepatocellular carcinoma. Br J Cancer 2010;102:
981–986.
28. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II
study of gemcitabine and oxaliplatin in combination
with bevacizumab in patients with advanced hepato-
cellular carcinoma. J ClinOncol 2006;24:1898–1903.
29. Vlachogiannakos J, Goulis J, Patch D et al. Pri-
mary prophylaxis for portal hypertensive bleeding
in cirrhosis. Aliment Pharmacol Ther 2000;14:851–
860.
30. ThomasMB,Morris JS, ChadhaR et al. Phase II
trial of the combination of bevacizumab and erlo-
tinib in patients who have advanced hepatocellular
carcinoma. J Clin Oncol 2009;27:843–850.
31. Shalaby F, Rossant J, Yamaguchi TP et al. Fail-
ureofblood-island formationandvasculogenesis in
flk-1-deficientmice. Nature 1995;376:62–66.
32. Takahashi S. Vascular endothelial growth fac-
tor (VEGF), VEGF receptors and their inhibitors for
antiangiogenic tumor therapy. Biol Pharm Bull
2011;34:1785–1788.
33. Spratlin JL, Cohen RB, Eadens M et al. Phase I
pharmacologic and biologic study of ramucirumab
(IMC-1121B), a fully human immunoglobulin G1
monoclonal antibody targeting the vascular endo-
thelial growth factor receptor-2. J Clin Oncol 2010;
28:780–787.
34. Zhu AX, Finn RS, Mulcahy MF et al. A phase II
study of ramucirumab as first-line monotherapy in
patients (pts) with advanced hepatocellular carci-
noma (HCC). J Clin Oncol 2010;28(suppl 15):4083.
35.Wong CI, Koh TS, Soo R et al. Phase I and bio-
marker study of ABT-869, a multiple receptor ty-
rosine kinase inhibitor, in patients with refractory
solid malignancies. J Clin Oncol 2009;27:4718–
4726.
36. Toh H, Chen P, Carr BI et al. Linifanib phase II
trial in patientswith advanced hepatocellular carci-
noma (HCC). J Clin Oncol 2010;28(suppl 15):4038.
37. Alberts SR, Fitch TR, Kim GP et al. Cediranib
(AZD2171) in patients with advanced hepatocellu-
lar carcinoma: A phase II north central cancer treat-
ment group clinical trial. Am J Clin Oncol 2012;35:
329–333.
38. Huynh H, Ngo VC, Fargnoli J et al. Brivanib al-
aninate, a dual inhibitor of vascular endothelial
growth factor receptorand fibroblast growth factor
receptor tyrosine kinases, induces growth inhibi-
tion inmousemodels of human hepatocellular car-
cinoma. Clin Cancer Res 2008;14:6146–6153.
39. Bhide RS, Lombardo LJ, Hunt JT et al. The anti-
angiogenic activity in xenograft models of brivanib,
a dual inhibitor of vascular endothelial growth fac-
tor receptor-2 and fibroblast growth factor recep-
tor-1 kinases.Mol Cancer Ther 2010;9:369–378.
40. Tovar V, Cornella H, VillanuevaA et al. FGF sig-
naling dysregulation inHCCand role in thedevelop-
ment of acquired resistance to anti-angiogenic
therapies. Paper presented at: 62nd Annual Meet-
ing of the American Association for the Study of
Liver Diseases; November 4–8, 2011; San Fran-
cisco, CA.
41. Park JW, Finn RS, Kim JS et al. Phase II, open-
label study of brivanib as first-line therapy in pa-
tients with advanced hepatocellular carcinoma.
Clin Cancer Res 2011;17:1973–1983.
42. Finn RS, Kang YK, Mulcahy M et al. Phase II,
open-label study of brivanib as second-line therapy
in patients with advanced hepatocellular carci-
noma. Clin Cancer Res 2012;18:2090–2098.
43. Llovet JM, Decaens T, Raoul J-L et al. Brivanib
versus placebo in patients with advanced hepato-
cellular carcinoma (HCC)who failedorwere intoler-
ant to sorafenib: results from the phase 3 BRISK-PS
study. J Hepatol 2012;56(suppl 2):S549.
44.Motzer RJ, Escudier B, Oudard S et al. Efficacy
of everolimus in advanced renal cell carcinoma: A
double-blind, randomised, placebo-controlled
phase III trial. Lancet 2008;372:449–456.
45.Motzer RJ, Escudier B, Oudard S et al. Phase 3
trial of everolimus for metastatic renal cell carci-
noma: Final results and analysis of prognostic fac-
tors. Cancer 2010;116:4256–4265.
46. Zhu AX, Abrams TA, Miksad R et al. Phase 1/2
studyofeverolimus inadvancedhepatocellular car-
cinoma. Cancer 2011;117:5094–5102.
47. Kanai F, Yoshida H, Tateishi R et al. A phase I/II
trial of the oral antiangiogenic agent TSU-68 in pa-
tients with advanced hepatocellular carcinoma.
Cancer Chemother Pharmacol 2011;67:315–324.
48. Bergers G, Hanahan D.Modes of resistance to
anti-angiogenic therapy. Nat Rev Cancer 2008;8:
592–603.
49.RiniBI,AtkinsMB.Resistance to targeted ther-
apy in renal-cell carcinoma. Lancet Oncol 2009;10:
992–1000.
50. Lieu C, Heymach J, Overman M et al. Beyond
VEGF: Inhibition of the fibroblast growth factor
pathway and antiangiogenesis. Clin Cancer Res
2011;17:6130–6139.
51. Casanovas O, Hicklin DJ, Bergers G et al. Drug
resistance by evasion of antiangiogenic targeting of
437Sampat, O’Neil
www.TheOncologist.com ©AlphaMed Press 2013
VEGFsignaling in late-stagepancreatic islet tumors.
Cancer Cell 2005;8:299–309.
52. Kopetz S, Hoff PM,Morris JS et al. Phase II trial
of infusional fluorouracil, irinotecan, and bevaci-
zumab for metastatic colorectal cancer: Efficacy
and circulating angiogenic biomarkers associated
with therapeutic resistance. J Clin Oncol 2010;28:
453–459.
53.GauglhoferC, SagmeisterS, SchrottmaierWet
al. Up-regulation of the fibroblast growth factor 8
subfamily in human hepatocellular carcinoma for
cell survival and neoangiogenesis. Hepatology
2011;53:854–864.
54.Cascone T, HerynkMH, Xu L et al. Upregulated
stromal EGFR and vascular remodeling in mouse
xenograft models of angiogenesis inhibitor-resis-
tant human lung adenocarcinoma. J Clin Invest
2011;121:1313–1328.
55.RapisardaA,HollingsheadM,UranchimegBet
al. Increased antitumor activity of bevacizumab in
combinationwith hypoxia inducible factor-1 inhibi-
tion.Mol Cancer Ther 2009;8:1867–1877.
56. Yuan P, Wang L, Wei D et al. Therapeutic inhi-
bition of Sp1 expression in growing tumors bymith-
ramycin a correlates directly with potent
antiangiogeniceffectsonhumanpancreaticcancer.
Cancer 2007;110:2682–2690.
57. Carmeliet P, Jain RK. Principles and mecha-
nisms of vessel normalization for cancer and other
angiogenic diseases. Nat Rev Drug Discov 2011;10:
417–427.
58. Huang H, Bhat A, Woodnutt G et al. Targeting
the ANGPT-TIE2 pathway in malignancy. Nat Rev
Cancer 2010;10:575–585.
59. Lee JH, Park JY, KimdoYet al. Prognostic value
of 18F-FDG PET for hepatocellular carcinoma pa-
tients treated with sorafenib. Liver Int 2011;31:
1144–1149.
60. Jiang T, Zhu AX, Sahani DV. Established and
novel imagingbiomarkers for assessing response to
therapy in hepatocellular carcinoma. J Hepatol
2012;58:169–177.
438 Antiangiogenic Therapies for Advanced HCC
©AlphaMed Press 2013
